Key Developments and Trends Steering the Vasomotor Menopausal Symptoms (VMS) Treatment Market Forward: Increasing The Emphasis On Drug Approvals To Provide Better Treatment Options
Discover trends, market shifts, and competitive outlooks for the vasomotor menopausal symptoms (vms) treatment industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Is the Estimated Market Size of the Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2029?
The market for the treatment of vasomotor menopausal symptoms (VMS) has witnessed significant growth recently. The market size is projected to increase from $17.86 billion in 2024 to $19.19 billion in 2025, marking a compound annual growth rate (CAGR) of 7.5%. Factors such as hormone replacement therapy (HRT), awareness about menopause, advancements in pharmaceuticals, and consumer demand have contributed to this growth in the historical period.
Over the coming years, the treatment market for vasomotor menopausal symptoms (VMS) is predicted to experience significant growth. Its value is expected to reach $24.81 billion in 2029, with a compound annual growth rate (CAGR) of 6.6%. This projected growth during the forecast period can be credited to factors such as personalized medication, innovations in non-hormonal treatments, dietary and nutritional intervention strategies, and the integration of telemedicine and digital health. The forecast period will also see prime market trends like natural and alternative treatments, botanical and herbal solutions, menopause support forums, and cognitive behavioral therapy (cbt).
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
The surge in the population of menopausal women is set to drive the vasomotor menopausal symptom’s treatment market’s expansion. Menopause, a biological process that signifies the end of a woman’s fertility period, is a critical period in every woman’s life, happening between the ages of 45 and 55, with most women experiencing it around the age of 51. The growth in the number of women at this stage, needing management of symptoms like hot flashes and vaginal dryness, is a significant factor pushing the vasomotor menopausal symptoms (VMS) treatment market’s growth. As estimated by the US-based Cuyuna Regional Medical Center in November 2022, by 2025, 1.1 billion women globally are expected to be in menopause, owing to increased life expectancy. They also projected a 1.6% annual increase in the menopausal population until 2060. Hence, the rising population of menopausal women is spurring the growth of the vasomotor menopausal symptom’s treatment market. Furthermore, governmental health initiatives focused on menopausal women are anticipated to further the growth of the vasomotor menopausal symptom’s treatment market. These initiatives consist of funding for studies on menopausal transition, disease prevention, and research related to pharmacological, clinical, and epidemiological aspects. They form part of a comprehensive strategy focusing on numerous women’s health issues. To illustrate, the January 2023 report from the Government of New South Wales in Australia mentioned a government dedication of $40.3 million from 2022-2023 to 2025-2026 to initiate up to 16 new programs for women suffering from severe menopausal symptoms. Consequently, these governmental health initiatives for menopausal women are steering the growth of the vasomotor menopausal symptoms’ treatment market.
Which Segments in the Vasomotor Menopausal Symptoms (VMS) Treatment Offer the Most Growth?
The vasomotor menopausal symptoms (VMS) treatment market covered in this report is segmented –
1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants
2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)
6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives
7) Phenytoin: Hydantoins
8) Phenobarbital: Barbiturates
9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13051&type=smp
What Are the Fastest-Growing Geographies in the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Current Market Growth and Trends in the Vasomotor Menopausal Symptoms (VMS) Treatment Industry?
Major firms in the vasomotor menopausal symptoms treatment market, such as Veozah, are advancing their products and securing approvals to deliver fresh treatment solutions and address patients’ unmet medical requirements. The licensing of novel menopause drugs offers enhanced effectiveness and safety compared to currently available treatments. For example, in May 2023, the FDA, a federal agency based in the US, granted approval to Japan’s Astellas Pharma Inc for their product, Veozah (fezolinetant) 45 mg to be taken once daily. This drug is used for treating mild to severe menopausal vasomotor symptoms (VMS), making it the first nonhormonal neurokinin 3 (NK3) receptor antagonist approved for this uses. It’s a hormone-free treatment that interferes with a brain pathway that manages these symptoms. It offers an additional treatment option for women experiencing these symptoms, especially those who cannot or choose not to undergo hormone therapy. The approval of Veozah underlines its promising future as a new drug for managing menopausal symptoms.
View the full report here:
What Are the Key Elements That Define the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
Vasomotor menopausal symptoms (VMS) treatment refers to the medical interventions and therapies used to alleviate or manage the various symptoms associated with menopause. Women experience the symptoms of VMS during menopause, which include hot flashes and night sweats. The treatment works by balancing hormone levels in the body and altering neurotransmitters in the brain.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13051
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
